Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,040,496
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.63
  • Price/Sales 8.39
  • Price/Cash Flow 23.60
  • Price/Book 18.92

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.58 +7.28%
on 12/19/17
56.74 -0.58%
on 01/17/18
+3.90 (+7.43%)
since 12/15/17
3-Month
48.77 +15.67%
on 11/09/17
56.74 -0.58%
on 01/17/18
+7.10 (+14.40%)
since 10/17/17
52-Week
32.83 +71.82%
on 02/02/17
56.74 -0.58%
on 01/17/18
+20.21 (+55.83%)
since 01/17/17

Most Recent Stories

More News
Endocrine Society introduces new journal editors

Noted diabetes expert Daniel J. Drucker, MD, has been named Editor-in-Chief of Endocrine Reviews, a peer-reviewed journal published by the Endocrine Society.

NVO : 56.41 (+1.99%)
Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.

XOMA : 32.63 (+3.39%)
SCMP : 18.00 (-0.28%)
NVO : 56.41 (+1.99%)
EXEL : 27.49 (-7.28%)
Teva's Trisenox Gets FDA Approval as First-Line Treatment

Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

MYL : 46.78 (+0.30%)
NVO : 56.41 (+1.99%)
AGN : 176.72 (-1.09%)
TEVA : 21.48 (+0.33%)
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU

Global markets endured a volatile week, guided by opposing factors.

AZN : 35.08 (+0.26%)
NVO : 56.41 (+1.99%)
MT : 36.68 (-0.08%)
ITUB : 14.53 (+1.61%)
INFY : 18.12 (+1.91%)
VALE : 13.35 (+1.37%)
PHG : 40.02 (-1.01%)
HMC : 36.33 (+1.68%)
Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.

NVO : 56.41 (+1.99%)
JNJ : 146.98 (+0.08%)
MRK : 62.03 (-0.06%)
PFE : 37.18 (+1.58%)
GSK : 38.15 (+0.61%)
SNY : 44.60 (-0.69%)
BMY : 61.85 (+3.22%)
Diabetes Devices Market to reach US$66,053.1 mn by 2025, globally: Transparency Market Research

The global diabetes devices market has been observed to feature a moderately consolidated vendor landscape, according to a report from Transparency Market Research (TMR. Prominent names in the global diabetes...

NVO : 56.41 (+1.99%)
LLY : 86.21 (+1.08%)
MDT : 86.11 (+0.93%)
Why is Novo Nordisk Stock Up More Than 50% in Past Year?

We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.

XOMA : 32.63 (+3.39%)
SCMP : 18.00 (-0.28%)
NVO : 56.41 (+1.99%)
EXEL : 27.49 (-7.28%)
DIAGNOS Announces the Management of the Flagship Nuevo Yo Program by Novo Nordisk

DIAGNOS Inc. ("DIAGNOS", "the Corporation" or "we") (TSX VENTURE:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence...

ADK.VN : 0.120 (+4.35%)
NVO : 56.41 (+1.99%)
DGNOF : 0.0886 (-2.64%)
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes

Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.

AZN : 35.08 (+0.26%)
NVO : 56.41 (+1.99%)
MRK : 62.03 (-0.06%)
SNY : 44.60 (-0.69%)
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection

Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.

XOMA : 32.63 (+3.39%)
SCMP : 18.00 (-0.28%)
NVO : 56.41 (+1.99%)
EXEL : 27.49 (-7.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 57.20
1st Resistance Point 56.80
Last Price 56.41
1st Support Level 55.95
2nd Support Level 55.50

See More

52-Week High 56.74
Last Price 56.41
Fibonacci 61.8% 47.61
Fibonacci 50% 44.79
Fibonacci 38.2% 41.96
52-Week Low 32.83

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.